Clinical Trials Browser

Interventional × Ado-Trastuzumab Emtansine × Thoracic × Clear all

NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Phase 2 Active not recruiting

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

NCT05650879 2025-07-15

HER2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02314481 2025-05-23

DARWINII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03784599 2022-11-10

TRAEMOS

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

49 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung